Tumor Heterogeneity and Drug Resistance
Friday, June 21, 2024
8:30 a.m. – 4:35 p.m.
The 22nd Annual Koch Institute Symposium on Tumor Heterogeneity and Drug Resistance will take place on Friday, June 21, 2024. This year's speaker lineup features a robust array of experts, both internal to MIT and from external institutions around the US and abroad, representing multiple scientific disciplines and technical approaches that seek to better understand patient-specific variation in cancer progression and response to therapy.
We cordially invite scientists, oncologists, and any other member of the biomedical community to join us in a day of engaging talks, stimulating conversations with colleagues, and of course camaraderie in our collective fight against cancer. As we explore issues ranging from divergent single-cell states and plasticity to mechanisms of resistance through signaling and epigenetics, please consider joining us at this year’s summer symposium hosted by MIT’s nationally recognized basic cancer center.
Agenda
8:30 AMCheck-in
9:00 - 9:05 AMOpening Remarks
Matthew Vander Heiden
Director, Koch Institute at MIT
9:05 AMSession One: Linking Cancer Cell State to Function
Chairs: Katie Galloway and Paul Blainey
Koch Institute at MIT
Cédric Blanpain | Keynote
Université Libre de Bruxelles
"Mechanisms regulating tumor transition states"
Karuna Ganesh
Memorial Sloan Kettering Cancer Center
"Dissecting and targeting plasticity in metastatic colorectal cancer"
10:30 AM – 11:00 AM Break
Sydney Shaffer
University of Pennsylvania
"Tracking cell state plasticity in injury and cancer"
Alex Shalek
Koch Institute at MIT
"Does cell state matter in cancer?"
12:00pm – 1:30pm Lunch Break
1:30 PMSession Two: Integrating Genomics & Signaling in Tumor Drug Response
Chairs: Anders Hansen and Yadira Soto-Feliciano
Koch Institute at MIT
Paul Mischel
Stanford University
"Extrachromosomal DNA (ecDNA): Cancer’s dynamic circular genome"
Rameen Beroukhim
Dana-Farber Cancer Institute and Harvard Medical School
"Effects of positive and negative selection on cancer genomes"
2:30 PM – 3:00 PM Break
Neal Rosen
Memorial Sloan Kettering Cancer Center
"Mechanisms of primary resistance to RAS inhibitors"
Michael Yaffe
Koch Institute at MIT
"CRISPR-based interrogation of therapeutic resistance in ovarian cancer identifies known and novel targets"
Katherine Chiappinelli
George Washington University
"Targeting transposable elements to reverse cancer immune evasion"
4:30pm – 4:35pmConcluding Remarks
Matthew Vander Heiden
Director, Koch Institute at MIT